DBV Technologies : Announces Filing of its 2016 "Document de Référence" and Annual Report on Form 20-F
(Thomson Reuters ONE) -
Press Release
Montrouge, France, March 22, 2017
DBV Technologies Announces Filing of its 2016 "Document de Référence" and Annual
Report on Form 20-F
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT) today announced the filing of its 2016 Annual Report "Document de
Référence" for the year ended December 31, 2016 with the French market authority
"Autorité des Marchés Financiers" (AMF) and the filing of its Annual Report on
Form 20-F for the year ended December 31, 2016 with the U.S. Securities and
Exchange Commission (SEC).
These documents can be accessed on the Investor Relations section of the
Company's website at www.dbv-technologies.com. In addition, the "Document de
Référence" is available on the AMF's website at www.amf-france.org and the Form
20-F is available on the SEC's website at www.sec.gov. Printed copies of the
"Document de Référence" are available at the Company's headquarters and
registered office located at 177-181 avenue Pierre Brossolette 92120 Montrouge,
France. Any shareholder can request a printed copy of the Form 20-F, free of
charge, upon request. Requests should be directed to DBV Technologies, Attn:
Investor Relations, 177-181 avenue Pierre Brossolette 92120 Montrouge, France.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contact
Susanna Mesa
Senior Vice President, Strategy
+1 212-271-0861
susanna.mesa(at)dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia(at)webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
pdf version :
http://hugin.info/156437/R/2089851/789068.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 22.03.2017 - 22:30 Uhr
Sprache: Deutsch
News-ID 531978
Anzahl Zeichen: 3850
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 193 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies : Announces Filing of its 2016 "Document de Référence" and Annual Report on Form 20-F"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
